11 completed, 3 terminated, 2 not yet recruiting, 2 recruiting. 8 Phase 2, 4 Not applicable, 4 Phase 3, 2 Phase 1, 1 Phase 4.
Follow Coccidioidomycosis: new trials by email Literature Review of Coccidioidomycosis trials Research Report on Coccidioidomycosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Platform Trial for Salvage Consolidation Therapy in Dimorphic Fungi Oteseconazole - Coccidioidomycosis, Blastomycosis | Phase 2 | Not yet recruiting | University of Minnesota | 30 | 2026-12-01 | 2026-09-04 |
| A Phase II Randomized Study to Evaluate Measures for Endpoint Derivation in Patients With Progressive or Refractory Disseminated Coccidioidomycosis Treated With Olorofim Plus Baseline Standard of Care or Placebo Plus Baseline Standard of Care Olorofim, Placebo - Coccidioidomycosis, Disseminated Fungal Infection | Phase 2 | Not yet recruiting | F2G Ltd | 50 | 2026-12-01 | 2026-09-22 |
| Olorofim in Early Coccidioidal Meningitis olorofim - Coccidioidal Meningitis | Phase 2 | Recruiting | Fariba Donovan | 12 | 2026-06-01 | 2026-07-27 |
| To Find Effectiveness of Stretching Versus Soft Tissue Mobilization in Coccydynia in Postpartum Females Stretching, Soft Tissue Mobilization - Coccidioidomycosis | Not applicable | Active not recruiting | Superior University | 46 | 2025-03-20 | 2025-04-06 |
| A Study on Rare Dermatological Infections Conducted at Three Major Reference Hospitals in Costa Rica. Sporotrichosis, Chromomycosis | Completed | Caja Costarricense de Seguro Social | 95 | 2023-12-11 | 2024-07-29 | |
| SUBA-Itraconazole Therapy for Coccidioidomycosis Refractory or Intolerant to Fluconazole SUBA-itraconazole - Coccidioidomycosis, Valley Fever | Phase 2 | Withdrawn | George R Thompson | 2021-05-15 | 2021-07-19 | |
| Safety and Pharmacokinetics of VT-1598 Placebo, VT-1598 - Coccidioidomycosis | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 48 | 2020-09-29 | 2024-07-26 |
| An Observational Study to Assess the Prevalence and Outcomes of Primary Pulmonary Coccidioidomycosis in Persons Aged > / = 14 Years Presenting With Community Acquired Pneumonia (CAP) in Endemic Areas (SAnds-PPC) Coccidioidomycosis, Pneumonia | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 651 | 2019-02-14 | 2024-01-19 | |
| Endemic Mycoses Treatment With SUBA-itraconazole vs Itraconazole SUBA itraconazole, Conventional itraconazole - Invasive Fungal Infections | Phase 2 / Phase 3 | Completed | University of Alabama at Birmingham | 88 | 2018-09-17 | 2023-07-07 |
| Improving the Appearance of Skin and Hair in Patients Undergoing Valley Fever Treatment Cholesterol-containing moisturizers - Valley Fever, Coccidioidomycosis | Not applicable | Terminated | University of Arizona | 14 | 2018-08-01 | 2021-06-04 |
| Evaluate F901318 (Olorofim) Treatment of Invasive Fungal Infections in Participants Lacking Treatment Options Olorofim - Invasive Fungal Infections | Phase 2 | Completed | F2G Biotech GmbH | 203 | 2018-06-06 | 2024-07-10 |
| Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment Ibrexafungerp - Invasive Candidiasis, Mucocutaneous Candidiasis | Phase 3 | Completed | Scynexis, Inc. | 233 | 2017-04-01 | 2024-11-20 |
| Sertraline in Addition to Standard of Care Treatment for Coccidioidomycosis Sertraline - Coccidioidomycosis | Phase 2 | Withdrawn | University of California, San Francisco | 2016-11-01 | 2022-03-21 | |
| Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever) Fluconazole, Placebo - Coccidioidomycosis | Phase 4 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 72 | 2015-12-29 | 2019-07-05 |
| Pathogenesis and Genetics of Disseminated or Refractory Coccidioidomycosis Coccidioidomycosis | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 400 | 2014-09-02 | 2026-10-13 | |
| Risk of Coccidioidomycosis in Patients Receiving Anti-TNF and Other Biologic Agents for an Inflammatory Arthritis Coccidioidomycosis, Rheumatoid Arthritis | Completed | University of Arizona | 598 | 2007-10-01 | 2015-12-14 | |
| Safety and PK of Nikkomycin Z for Coccidioides Pneumonia Treatment nikkomycin Z, Placebo - Coccidioidomycosis | Phase 1 / Phase 2 | Terminated | University of Arizona | 6 | 2007-09-01 | 2025-04-16 |
| POS vs FLU for First Line Treatment of Coccidioidomycosis (Study P04558Am1)(COMPLETED) Posaconazole, Fluconazole - Coccidioidomycosis | Phase 3 | Completed | Merck Sharp & Dohme LLC | 16 | 2007-05-01 | 2017-04-11 |
| A Multi-center Study of Spherule-Derived Coccidioidin Spherule-derived coccidioidin - Coccidioidomycosis | Phase 3 | Completed | Nielsen BioSciences, Inc. | 113 | 2005-05-01 | 2013-10-29 |
| A Study of Fluconazole in the Prevention of Fungal Infections in HIV-Infected Patients Living in Areas Where Fungal Infections Are Common Fluconazole - Mycoses, HIV Infections | Not applicable | Completed | Pfizer | 2005-06-24 |
Showing 20 of 21. Sign in to see all of them.
Blastomycosis (4) · Histoplasmosis (3) · Invasive Fungal Infections (3) · Acquired Immunodeficiency Syndrome (2) · Community-Acquired Pneumonia (2) · HIV Infections (2) · Mycoses (2) · Pneumonia (2) · AIDS-Related Complex (1) · AIDS-Related Opportunistic Infections (1) · Actinomycosis (1) · Arthritis, Rheumatoid (1) · Aspergillosis, Allergic Bronchopulmonary (1) · Bacterial Infections and Mycoses (1)
Bacterial Infections and Mycoses (20) · Infections (20) · Mycoses (19) · Lung Diseases (6) · Respiratory Tract Diseases (6) · Respiratory Tract Infections (6) · Immune System Diseases (5) · Skin and Connective Tissue Diseases (5) · Dermatomycoses (4) · Lung Diseases, Fungal (4) · Skin Diseases (4) · Genital Diseases (3) · Skin Diseases, Infectious (3) · Urogenital Diseases (3) · Blood-Borne Infections (2)
Fluconazole (4) · olorofim (3) · Itraconazole (2) · Muscle Stretching Exercises (1) · Sertraline (1) · VT-1598 (1) · ibrexafungerp (1) · nikkomycin (1) · posaconazole (1)
National Institute of Allergy and Infectious Diseases (NIAID) (4) · University of Arizona (3) · Pfizer (2) · Caja Costarricense de Seguro Social (1) · F2G Biotech GmbH (1) · F2G Ltd (1) · Fariba Donovan (1) · George R Thompson (1) · Merck Sharp & Dohme LLC (1) · Nielsen BioSciences, Inc. (1) · Scynexis, Inc. (1) · Superior University (1) · University of Alabama at Birmingham (1) · University of California, San Francisco (1) · University of Minnesota (1)
United States (16) · Germany (2) · Netherlands (2) · Pakistan (2) · Spain (2) · United Kingdom (2) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · Costa Rica (1) · Egypt (1) · France (1) · Israel (1) · Panama (1)
George R Thompson, MD (2) · Andrej Spec, MD (1) · Berchman A Vaz, MD, PhD (1) · Brad Sawtelle, M.D. (1) · Daniel E Barquero Orias, MD (1) · David E Nix, Pharm D (1) · Fariba Donovan, MD, PhD (1) · George R. Thompson, MD (1) · Harry S Nielsen, Ph.D. (1) · Matthew Pullen, MD (1) · Neil Ampel, M.D. (1) · Peter G Pappas, MD (1) · Royce Johnson, M.D. (1) · Sharon Chen (1) · Simon Paul, MD (1)
PMID 32457106, PMID 38440302, PMID 40541222, PMID 41914555, PMID 42008658, PMID 42475691
2017 (1)